Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena’s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals. Abzena works with most of the top 20 biopharmaceutical… Read more
ADC Bio is an innovative biotechnology company developing new process technology to speed, simplify and significantly lower the production costs of ADCs. The company are specialists in state-of-the-art bio-conjugation techniques and cytotoxin drug-linker synthesis, assisting drug developers to deliver their next generation ADCs. Our proprietary ‘Lock-Release’ technology aims to become a new paradigm in the way ADCs are developed and manufactured by providing fast, simple and robust conjugation processes. www.adcbio.com
Baxter BioPharma Solutions, a business unit of Baxter, partners with pharmaceutical companies to support their commercialization objectives by providing scientific expertise, sterile contract manufacturing solutions, parenteral delivery systems, and customized support services needed to meet the unique challenges that parenteral products face.
BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. BSP Pharmaceuticals is focused on innovative therapies such as Proteosome Inhibitors, ADCs , Liposomal formulations, handling the major platforms of ADC compounds currently in clinical and commercial phase.
CARBOGEN AMCIS combines world-class chemistry skills to provide seamless drug development and commercialization services for leading pharmaceutical and biotechnology companies. Through our customised offering we provide an array of integrated services to support the fast supply of complex Antibody Drug Conjugates (ADCs). Our infrastructure is fully GMP compliant and includes a workshop dedicated to ADCs in Switzerland and a formulation site with lyophilization capabilities in France.
CordenPharma is a leader in the development and manufacturing of highly potent warheads and linkers for ADCs. From its two facilities CordenPharma Boulder and CordenPharma Colorado, both in Boulder, Colorado, CordenPharma offers development and manufacturing services for clinical and commercial supply of highly potent small molecules, including peptides (solution & solid phase). Both facilities have over 25 years of experience with highly potent compounds and the demonstrated ability to safely work with products <1ng/m3 OEL.
Heraeus, the precious metals and technology group headquartered in Hanau, Germany, is a global, private company with 160 years of tradition. Our fields of competence include precious metals, materials, and technologies, sensors, biomaterials, and medical products, as well as dental products, quartz glass, and specialty light sources. With product revenues of €4.1 billion and precious metal trading revenues of €17.9 billion, as well as more than 12,900 employees in over 120 subsidiaries worldwide, Heraeus holds a leading position in its global markets.
Iksuda Therapeutics (formally Glythera) is a pre-clinical stage company developing ADCs for difficult to treat solid tumours. Our ADCs are centered around our proprietary PermaLInk® conjugation platform which provides conjugation stability by design.
Through PermaLink, we aim to develop more effective ADCs by leveraging the broad tumour activity associated with ultra-potent DNA damaging payloads, combined with clinically relevant targets… Read More.